Welcome to our dedicated page for CARLSMED news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on CARLSMED stock.
Carlsmed, Inc. reports developments in AI-enabled personalized spine surgery solutions for lumbar and cervical procedures. The company designs, manufactures and markets the aprevo® technology platform, which combines customized surgical planning with patient-specific implants for spine fusion procedures sold primarily to hospitals and ambulatory surgical centers.
Carlsmed news commonly covers quarterly financial results, revenue guidance, clinical data for aprevo® personalized implants, product updates for cervical and patient-specific fixation systems such as corra™, and management presentations at healthcare and medical technology investor conferences.
Carlsmed (CARL) has promoted Jeff Bertolini to Chief Operating Officer, effective immediately as of the September 8, 2026 announcement.
Bertolini joined Carlsmed in September 2024 and most recently served as Senior Vice President, Operational Excellence, after previously holding the role of Vice President of Advanced Manufacturing Technologies. Before joining Carlsmed, he held senior operations and technology leadership positions at SI-BONE, NuVasive, and US Surgical.
The company credits Bertolini with driving the deployment of advanced technologies across its digital production process to accelerate scale and capabilities for its AI-enabled personalized spine surgery solutions. He holds an MBA from Rensselaer Polytechnic Institute, a Bachelor of Science in Procurement and Logistics Management from Arizona State University, and has completed executive programs at the Wharton School and MIT Professional Education in Applied Data Science.
Carlsmed (Nasdaq: CARL) reported second quarter 2026 revenue of $18.9 million, up 57% year-over-year from $12.1 million, with gross margin improving to 76.8% from 73.4%. Gross profit rose to $14.5 million while operating expenses increased to $25.6 million, driving a net loss of ($10.5) million versus ($6.8) million a year earlier. Adjusted EBITDA was ($8.6) million compared to ($6.2) million. The company ended June 30, 2026 with $89.3 million in cash, equivalents, restricted cash, short-term investments and marketable securities.
Carlsmed raised its full-year 2026 revenue guidance to $74–$78 million from $72–$77 million, implying over 50% growth at the midpoint versus 2025. Management highlighted over 60% growth in trained surgeon users, aprevo® cervical reaching ~10% of quarterly revenue, and a finalized CMS IPPS rule adding three new MS-DRG codes with favorable reimbursement for inpatient aprevo® lumbar procedures effective October 1, 2026.
Carlsmed (Nasdaq: CARL) announced that the Centers for Medicare & Medicaid Services finalized a favorable reimbursement policy for inpatient aprevo® Lumbar spinal fusion procedures in the FY27 IPPS Final Rule. Effective October 1, 2026, these procedures are reassigned to three new MS-DRGs (523, 524, 525), making all inpatient aprevo® Lumbar fusions eligible for reimbursement under these codes.
Carlsmed (Nasdaq: CARL) will participate in two upcoming virtual investor conferences. Management will attend the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference with one-on-one meetings on Monday, August 10, 2026. Carlsmed will also join the Bank of America SMID Cap Virtual Conference, featuring a fireside chat on Wednesday, August 12, 2026 at 11:00 AM ET, with a live and archived webcast available in the Events & Presentations section of its investor website.
Carlsmed (Nasdaq: CARL) announced it will report its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Management will host a conference call and live webcast at 1:30 PM Pacific Time, accessible via the Events & Presentations section of its investor website, with a replay archived afterward.
Carlsmed (NASDAQ: CARL) reported Q1 2026 results: $16.1M revenue (58% YoY), $12.4M gross profit, gross margin 77.1%, and net loss of $8.7M. Adjusted EBITDA was -$7.5M. Cash and equivalents totaled $97.1M. Full-year 2026 revenue guidance raised to $72–$77M from $70–$75M.
Clinical progress includes a published study showing a 74% reduction in reoperations for aprevo and early procedures for corra and aprevo bi-lateral posterior.
Carlsmed (Nasdaq: CARL) announced CEO Mike Cordonnier will participate in multiple investor conferences in May–June 2026, including Bank of America Global Healthcare (May 12), Jefferies Global Healthcare (June 4), Goldman Sachs Global Healthcare (June 10) and Truist MedTech (June 16).
Live webcasts will be available for scheduled fireside chats and archived on the company’s Events and Presentations page at investors.carlsmed.com; management will hold one-on-one meetings on select dates.
Carlsmed (Nasdaq: CARL) will report first quarter 2026 results after market close on Tuesday, May 5, 2026. Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time with a replay available shortly after and archived on the company website.
Participant registration is required via the provided registration link; callers should dial in 5–10 minutes before the start time.
Carlsmed (Nasdaq: CARL) announced that CEO and Chairman Mike Cordonnier will present at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET.
A live webcast will be available to registered participants, and a replay will be posted after the presentation.
Carlsmed (Nasdaq: CARL) reported strong revenue growth with Q4 2025 revenue $15.2M (+61% YoY) and full-year 2025 revenue $50.5M (+86% YoY). Gross margin expanded to 75.3% for 2025 and cash resources were $109.9M at year-end. Management provided 2026 revenue guidance of $70–$75M.
Company highlighted published 2-year aprevo lumbar outcomes showing a 74% reduction in revision rates and multiple product and first-in-human procedural milestones in February 2026.